Trials / Completed
CompletedNCT00551876
Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)
A Randomized, Double-Blind, Parallel, Multicenter Study to Evaluate the Efficacy and Safety of Simvastatin Monotherapy Compared With Simvastatin Plus Ezetimibe (SCH 58235) in Type 2 Diabetic Patients Treated With Thiazolidinediones
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 214 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the addition of ezetimibe 10 mg daily to ongoing 20 mg simvastatin daily will reduce LDL Cholesterol to a greater extent than increasing the dose of simvastatin to 40 mg daily in Type 2 diabetics treated with Thiazolidinediones (TZD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0653, ezetimibe / Duration of Treatment: 30 Weeks | |
| DRUG | Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks |
Timeline
- Start date
- 2001-12-01
- Primary completion
- 2003-01-01
- Completion
- 2003-01-01
- First posted
- 2007-10-31
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00551876. Inclusion in this directory is not an endorsement.